Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death.
Zhaoyang HuFeng JuLei DuGeoffrey W AbbottPublished in: Cardiovascular diabetology (2021)
Pretreatment with empagliflozin protects the heart from subsequent severe lethal ventricular arrhythmia induced by myocardial ischemia and reperfusion injury. These protective benefits may occur as a consequence of activation of the ERK1/2-dependent cell-survival signaling pathway in a glucose-independent manner.
Keyphrases
- signaling pathway
- heart failure
- pi k akt
- left ventricular
- atrial fibrillation
- catheter ablation
- drug induced
- high glucose
- acute myocardial infarction
- diabetic rats
- epithelial mesenchymal transition
- induced apoptosis
- cell proliferation
- early onset
- cerebral ischemia
- blood glucose
- adipose tissue
- brain injury
- percutaneous coronary intervention
- endothelial cells
- subarachnoid hemorrhage
- endoplasmic reticulum stress